CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis

CSA Medical Inc | October 22, 2020

CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy, today announced the first patient treated in the SPRAY-CB, U.S. pivotal trial utilizing the RejuvenAir® System for COPD with Chronic Bronchitis at Temple University. Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University (LKSOM) and Director of the Temple Lung Center, and principal investigator completed the procedure on October 14th.  "We are pleased to have performed the first procedure in this landmark pivotal trial, building on the European data in which patients achieved meaningful improvements in their cough and overall quality of life," said Dr. Criner. "RejuvenAir Metered Cryospray is a promising new interventional tool that has the potential to reduce emergency hospital visits due to chronic bronchitis symptoms. This definitive intervention may provide a long-term benefit to millions of adults suffering with Chronic Bronchitis."

Spotlight

The FDA and Big Pharma agree that SKM could be the answer to the pharma data management mess. KASA is moving ahead, but there are many reasons to embrace SKM now.

Related News

Intec Pharma Announces New Research Collaboration Agreement with MSD

Intec Pharma | October 08, 2020

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery."

Read More

Upcoming Xtalks Webinar Will Discuss Pharmaceutical Commercial Launch Readiness With Secrets to De-Risk and Accelerate Success

XTALKS | July 18, 2020

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to optimize commercial launch readiness through insight, differentiation, efficiency and risk mitigation will lead the pack. Often teams, whether in a start-up, mid, or large pharma, lack extensive experience in commercial launch readiness. This influences the brand’s ability to meet forecast and achieve market access targets. Leveraging the breadth and depth of launch experience from scores of launches across primary care, rare disease, oncology and specialty, this webinar will discuss typical commercial launch readiness risk areas, best practices approaches for commercial readiness and securing market access and measurement.

Read More

PRACTICE MANAGEMENT

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

Ascentage Pharma | January 14, 2021

Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&D outline. Dr. Yang conveyed a generally welcomed introduction on the organization's item pipeline and clinical advancement progress. As a worldwide pioneer in the improvement of therapeutics focusing on the protein-to-protein collaborations, Ascentage Pharma has assembled a pipeline of exceptionally serious resources, a considerable lot of which with first-in-class or top tier possibilities (Table 1). Until now, Ascentage Pharma has gotten 33 clinical preliminary endorsements or clearances, with more than 40 clinical examinations on-circumventing the world. As a main biopharmaceutical organization zeroing in on the improvement of apoptosis-focusing on treatments, Ascentage Pharma has assembled a rich and strong pipeline, with five medication applicants focusing on the three key apoptotic pathways - Bcl-2, IAP, and MDM2-p53, and has progressed all these five competitors into clinical turn of events. APG-2575, the organization's orally-managed novel little atom Bcl-2 inhibitor, pulled in a lot of interest from the business and examination local area, as it is one of only a handful few Bcl-2 particular inhibitors, after venetoclax, that have entered clinical turn of events. It is additionally the principal China-created Bcl-2 inhibitor entering clinical turn of events. In December 2020, Ascentage Pharma delivered refreshed outcomes from the clinical investigations of APG-2575 in the therapy of backslid/obstinate ongoing lymphocytic lymphoma (r/r CLL) which have selected more than 30 patients. Starter results show that an exceptionally reassuring target reaction rate (ORR) of 70% has been reached in evaluable patients. At this meeting, Dr. Yang shared extra subtleties on these outcomes.

Read More

Spotlight

The FDA and Big Pharma agree that SKM could be the answer to the pharma data management mess. KASA is moving ahead, but there are many reasons to embrace SKM now.